Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
Camille Baumrucker , Lindsay Remer , Dido Franceschi , Alan S Livingstone , Francis Igor Macedo
Background: Esophageal cancer (EC) is historically a male dominant disease. Current evidence on the impact of gender on clinical presentation and survival outcomes of EC is limited by small sample size or single institution series. Methods: Patients with EC (stage I-III) were identified in the NCDB (2004-2016). Clinicopathologic and treatment characteristics of male and female patients were compared using Chi-square analysis. Kaplan-Meier and Cox multivariable regression were used to estimate overall survival (OS). Results: Of 62,893 patients included, most patients were male (77.7%). Adenocarcinoma was the most common subtype (66.7%). Squamous cell carcinoma was more predominant in females (57.1% vs. 26.5%, p<0.001). Females were older (68.5 vs. 66.1 yrs; p<0.001) and more likely African American (AA, 14% vs. 8.1%; p<0.001). Females presented with more local disease (stage I, 19.6% vs. 18.2%; p<0.001) while males presented with more locoregional disease (LRD, stage II/III, 80.4% vs 81.8%, p<0.001). Of those with LRD, females less frequently received chemotherapy (CT, 75.4% vs. 82.9%, p<0.001), radiation therapy (RT, 78.9% vs. 82.6%, p<0.001), and esophagectomy (EG, 28% vs. 40.5%, p<0.001). White females with LRD received less CT (76.2% vs. 83.9%, p<0.001), RT (79.5% vs. 83.3%, p<0.001), and EG (30.6% vs. 43.5%, p<0.001). AA females with LRD received less CT (71.9% vs. 75.2%, p=0.013) and RT (77.4% vs. 80.5%, p=0.013) but had similar rates of EG as AA males (p=0.476). Females had worse OS than males (18.1 vs. 19.7mo, p=0.001; cI: 23.5 vs. 31.9mo, p<0.001; LRD: 17.2 vs 18.3mo, p=0.473). White females had worse OS than white males (18.6 vs. 20.4mo, p<0.001) while AA females had better OS (13.5 vs. 12.6mo, p=0.001). White females who underwent EG had improved OS over white males (47.6 vs 38mo, p<0.001) while AA males and females who underwent EG had similar OS (p=0.473). Female gender, older age, AA race, high comorbidity score and clinical stage, and lack of access to CT, RT, and EG were independent predictors of mortality (Table 1). Conclusions: Females with EC seem to have less access to CT, RT, and EG with worse OS than males. Healthcare policies should focus on increasing access to standard treatments for female patients with EC.
HR | 95% CI | p-value | ||
---|---|---|---|---|
Age | 1.012 | 1.011-1.013 | <0.001* | |
Gender | Male | 1.126 | 1.099-1.154 | <0.001* |
Race | White (Ref) | |||
AA | 1.11 | 1.072-1.149 | <0.001* | |
Hispanic | 0.819 | 0.773-0.869 | <0.001* | |
Other | 0.806 | 0.756-0.86 | <0.001* | |
Insurance | Uninsured (Ref) | |||
Private | 0.727 | 0.686-0.77 | <0.001* | |
Medicaid/ Medicare | 0.804 | 0.759-0.851 | <0.001* | |
Other | 0.719 | 0.658-0.785 | <0.001* | |
Comorbidity Score (CDCC) | 0 (Ref) | |||
1 | 1.141 | 1.114-1.168 | <0.001* | |
2 | 1.288 | 1.244-1.334 | <0.001* | |
Area | Rural (Ref) | |||
Metro | 0.975 | 0.912-1.043 | 0.466 | |
Urban | 1.047 | 0.976-1.123 | 0.199 | |
Clinical Stage | LRD | 1.678 | 1.63-1.727 | <0.001* |
Histology | SCC | 1.03 | 1.006-1.054 | 0.013 |
RT | 0.885 | 0.858-0.913 | <0.001* | |
CT | 0.698 | 0.677-0.719 | <0.001* | |
EG | 0.442 | 0.432-0.452 | <0.001* |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Yicong Chen
2024 ASCO Annual Meeting
First Author: Karthik Ramakrishnan
2021 Gastrointestinal Cancers Symposium
First Author: Camille Baumrucker
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Jaffer A. Ajani